AEGEAN Sustains a Perioperative Advantage in Resectable Non-Small Cell Lung Cancer
Perioperative durvalumab continued to separate from chemotherapy alone in resectable non-small cell lung cancer at the second planned interim analysis of AEGEAN, reinforcing the value of immune checkpoint blockade across the surgical timeline. In this phase III, double-blind, placebo-controlled trial, the addition of durvalumab to neoadjuvant platinum-based chemotherapy, followed by adjuvant durvalumab after surgery, preserved the event-free survival advantage first seen earlier in the study. The updated analysis also showed numerical improvement in disease-free survival and overall survival, while the safety profile remained broadly aligned with prior experience for the individual agents.
The treatment strategy is biologically coherent. Platinum chemotherapy can debulk tumor burden and expose antigens, while durvalumab interrupts PD-L1 mediated immune evasion at a moment when residual micrometastatic disease may be most vulnerable. In the perioperative setting, that dual pressure can matter twice: before resection, when tumor priming may be strongest, and after resection, when immune surveillance must suppress recurrence from occult residual disease. AEGEAN was designed around that premise, and the updated outcomes show that the benefit does not evaporate with longer follow-up.
Event-Free Survival Remained Consistently Favorable
AEGEAN enrolled patients with treatment-naïve resectable disease spanning stage II to IIIB, including N2 involvement, and randomized them 1:1 to neoadjuvant platinum-based chemotherapy plus durvalumab or placebo for four cycles before surgery, then adjuvant durvalumab or placebo every 4 weeks for 12 cycles afterward. Efficacy was assessed in the modified intention-to-treat population of 740 patients, excluding those with documented EGFR or ALK aberrations. For disease-free survival, the analysis focused on the resected subpopulation.
As of May 10, 2024, with median follow-up of 25.9 months among censored patients, the event-free survival hazard ratio remained 0.69 with a 95% confidence interval of 0.55 to 0.88. The effect size did not drift toward neutrality as follow-up matured. Instead, the perioperative immunotherapy arm kept its lead, suggesting that the earlier separation reflected a genuine disease-control advantage rather than an early statistical artifact.
A sustained event-free survival signal in a curative-intent lung cancer trial carries real weight. In this setting, events include recurrence, progression preventing surgery, or death, so a lower hazard translates into fewer patients losing the chance at long-term remission before the treatment course is even complete. The finding supports a treatment model in which systemic therapy is not simply a bridge to surgery, but part of the curative intervention itself.
Disease-Free Survival Improved, While Overall Survival Remains Immature
Disease-free survival also favored perioperative durvalumab, with a hazard ratio of 0.66 and a 95% confidence interval of 0.47 to 0.92. Overall survival trended in the same direction, with a hazard ratio of 0.89 and a 95% confidence interval of 0.70 to 1.14. The OS result remains immature, and the confidence interval still crosses 1, so a definitive survival conclusion would be premature. Still, the numerical direction matters in a disease where relapse after surgery often announces itself as systemic failure rather than a purely local event.
The DFS signal fits the mechanism of action. If PD-L1 blockade clears microscopic disease persisting after resection, the first endpoint to move is often recurrence-free disease rather than all-cause mortality, especially when follow-up is still relatively short. Lung cancer recurrence after surgery can emerge quickly and often in distant sites, which makes disease-free survival a clinically meaningful intermediate readout in a perioperative study. The current data suggest that the immune effect is not confined to pathologic response at the time of surgery; it extends into the postoperative period where residual clones would otherwise have a chance to expand.
One sentence captures the clinical shift: the benefit did not stop at the operating room door.
Safety Remained Manageable, With More High-Grade Events During Adjuvant Therapy
Safety continued to look consistent with the known profiles of the trial drugs, but the updated analysis showed a higher rate of maximum grade 3/4 adverse events during adjuvant treatment in the durvalumab arm than in the placebo arm, 15.4% versus 10.6%. That difference deserves attention because the adjuvant period is when patients are recovering from major thoracic surgery and may have less physiologic reserve for immune-related toxicity or treatment interruptions. Even so, the abstract characterizes the overall safety profile as consistent with the individual agents, indicating no new safety pattern emerged with longer follow-up.
In practical terms, perioperative immunotherapy depends on careful choreography. Neoadjuvant treatment must avoid compromising operability, while adjuvant treatment must avoid derailing postoperative recovery or exposing patients to cumulative toxicity without benefit. The updated AEGEAN findings suggest that the regimen can be delivered within that framework, though the higher grade 3/4 event rate in the adjuvant phase reinforces the need for close monitoring, prompt toxicity recognition, and ongoing assessment of who is most likely to complete the full course.
Why These Results Matter for Curative-Intent Lung Cancer
For resectable non-small cell lung cancer, the central question has shifted from whether immunotherapy can work in advanced disease to how early it should be deployed when cure is still possible. AEGEAN supports moving PD-L1 blockade upstream and keeping it in place after surgery, rather than treating surgery as an endpoint that ends systemic therapy decisions. The updated data are especially important because perioperative trials live or die on durability: a fleeting preoperative response means little if micrometastatic relapse still dominates the long run.
The exclusion of patients with documented EGFR or ALK alterations also defines the population to which these results apply. The study therefore speaks most directly to patients with resectable disease lacking those actionable oncogenic drivers, where immunotherapy-based perioperative strategies are already shaping practice. In that subgroup, the durable EFS effect and favorable DFS direction strengthen the case for durvalumab as a perioperative option.
What remains unresolved is the final overall survival readout. The current OS estimate leans in the right direction, but the interval is still too wide for a hard claim of survival superiority. Longer follow-up will determine whether the event-free and disease-free advantages become a mortality benefit, or whether effective salvage therapy narrows the gap over time. For now, AEGEAN shows that perioperative durvalumab can hold its ground after surgery and beyond the first interim readout, while the community waits for the mature survival data that will define the long-term standard.